Ocumension Therapeutics H1 revenue jumps on higher ophthalmic sales
Ocumension Therapeutics said its H1 revenue surged, citing higher ophthalmic product sales.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.